tiprankstipranks
Scinai Immunotherapeutics Restructures Debt, Boosts Equity
Company Announcements

Scinai Immunotherapeutics Restructures Debt, Boosts Equity

Scinai Immunotherapeutics (SCNI) has released an update.

Don't Miss our Black Friday Offers:

Scinai Immunotherapeutics has successfully restructured its loan with the European Investment Bank, converting approximately $29 million of debt into preferred equity and reducing its debt balance to $273,000. This financial maneuver has elevated the company’s stockholders’ equity above the Nasdaq’s minimum requirement of $2.5 million, potentially bringing it back into compliance with listing standards. The preferred shares issued in the deal have specific terms, including a 12-month lock-up period and conversion restrictions to maintain the company’s investment profile.

For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskScinai Immunotherapeutics Reports Financial Turnaround and Growth
TipRanks Auto-Generated NewsdeskScinai Immunotherapeutics Gains Shareholder Confidence
TipRanks Auto-Generated NewsdeskScinai Immunotherapeutics to Hold Annual Shareholder Meeting
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App